The Propagation and Quantification of Two Emerging Oncolytic Viruses: Vesicular Stomatitis (VSV) and Zika (ZIKV)

  • Robert E. Means
  • Sounak Ghosh Roy
  • Samuel G. KatzEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 2097)


Developments in genetic engineering have allowed researchers and clinicians to begin harnessing viruses to target and kill cancer cells, either through direct lysis or through recruitment of antiviral immune responses. Two powerful viruses in the fight against cancer are the single-stranded RNA viruses vesicular stomatitis virus and Zika virus. Here, we describe methods to propagate and titer these two viruses. We also describe a simple cell-killing assay to begin testing modified viruses for increased potential killing of glioblastoma cells.


Oncolytic virus therapy Vesicular stomatitis virus Zika virus Glioblastoma Immunotherapeutics Viral titration Plaque assay Cell killing 


  1. 1.
    Kamta J, Chaar M, Ande A, Altomare DA, Ait-Oudhia S (2017) Advancing cancer therapy with present and emerging immuno-oncology approaches. Front Oncol 7:64. Scholar
  2. 2.
    Fountzilas C, Patel S, Mahalingam D (2017) Review: Oncolytic virotherapy, updates and future directions. Oncotarget 8(60):102617–102639. Scholar
  3. 3.
    Mazar J, Li Y, Rosado A, Phelan P, Kedarinath K, Parks GD, Alexander KA, Westmoreland TJ (2018) Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24. PLoS One 13(7):e0200358. Scholar
  4. 4.
    Wood H (2017) Neuro-oncology: a new role for Zika virus in glioblastoma therapy? Nat Rev Neurol 13(11):640–641. Scholar
  5. 5.
    Zhu Z, Gorman MJ, McKenzie LD, Chai JN, Hubert CG, Prager BC, Fernandez E, Richner JM, Zhang R, Shan C, Tycksen E, Wang X, Shi PY, Diamond MS, Rich JN, Chheda MG (2017) Zika virus has oncolytic activity against glioblastoma stem cells. J Exp Med 214(10):2843–2857. Scholar
  6. 6.
    Bishnoi S, Tiwari R, Gupta S, Byrareddy SN, Nayak D (2018) Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy. Viruses 10(2). Scholar
  7. 7.
    Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN (2008) Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 28(8):1882–1893. Scholar
  8. 8.
    Velazquez-Salinas L, Naik S, Pauszek SJ, Peng KW, Russell SJ, Rodriguez LL (2017) Oncolytic recombinant vesicular stomatitis virus (VSV) is nonpathogenic and nontransmissible in pigs, a natural host of VSV. Hum Gene Ther Clin Dev 28(2):108–115. Scholar
  9. 9.
    Chen Q, Wu J, Ye Q, Ma F, Zhu Q, Wu Y, Shan C, Xie X, Li D, Zhan X, Li C, Li XF, Qin X, Zhao T, Wu H, Shi PY, Man J, Qin CF (2018) Treatment of human glioblastoma with a live attenuated Zika virus vaccine candidate. MBio 9(5):e01683–e01618. Scholar
  10. 10.
    Baltimore D (1971) Expression of animal virus genomes. Bacteriol Rev 35(3):235–241PubMedPubMedCentralGoogle Scholar
  11. 11.
    Garber K (2006) China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 98(5):298–300. Scholar
  12. 12.
    Liang M (2018) Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets 18(2):171–176. Scholar
  13. 13.
    Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS (2015) Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2788. Scholar
  14. 14.
    Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbe C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL (2018) Randomized, open-label phase II study evaluating the efficacy and safety of Talimogene Laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol 36(17):1658–1667. Scholar
  15. 15.
    Betancourt D, Ramos JC, Barber GN (2015) Retargeting oncolytic vesicular stomatitis virus to human T-cell lymphotropic virus type 1-associated adult T-cell leukemia. J Virol 89(23):11786–11800. Scholar
  16. 16.
    Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6(7):821–825. Scholar
  17. 17.
    Koyama AH (1995) Induction of apoptotic DNA fragmentation by the infection of vesicular stomatitis virus. Virus Res 37(3):285–290CrossRefGoogle Scholar
  18. 18.
    Gaddy DF, Lyles DS (2005) Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol 79(7):4170–4179. Scholar
  19. 19.
    Schache P, Gurlevik E, Struver N, Woller N, Malek N, Zender L, Manns M, Wirth T, Kuhnel F, Kubicka S (2009) VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. Gene Ther 16(7):849–861. Scholar
  20. 20.
    Qi X, Du L, Chen X, Chen L, Yi T, Chen X, Wen Y, Wei Y, Zhao X (2016) VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein. Int J Oncol 49(1):123–132. Scholar
  21. 21.
    Bourgeois-Daigneault MC, Roy DG, Falls T, Twumasi-Boateng K, St-Germain LE, Marguerie M, Garcia V, Selman M, Jennings VA, Pettigrew J, Amos S, Diallo JS, Nelson B, Bell JC (2016) Oncolytic vesicular stomatitis virus expressing interferon-gamma has enhanced therapeutic activity. Mol Ther Oncolytics 3:16001. Scholar
  22. 22.
    Dick GW (1952) Zika virus. II. Pathogenicity and physical properties. Trans R Soc Trop Med Hyg 46(5):521–534CrossRefGoogle Scholar
  23. 23.
    Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, Marfel M, Holzbauer S, Dubray C, Guillaumot L, Griggs A, Bel M, Lambert AJ, Laven J, Kosoy O, Panella A, Biggerstaff BJ, Fischer M, Hayes EB (2009) Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 360(24):2536–2543. Scholar
  24. 24.
    Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, Salje H, Van Kerkhove MD, Abadie V, Garel C, Fontanet A, Mallet HP (2016) Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet 387(10033):2125–2132. Scholar
  25. 25.
    Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR (2016) Zika virus and birth defects—reviewing the evidence for causality. N Engl J Med 374(20):1981–1987. Scholar
  26. 26.
    Souza BS, Sampaio GL, Pereira CS, Campos GS, Sardi SI, Freitas LA, Figueira CP, Paredes BD, Nonaka CK, Azevedo CM, Rocha VP, Bandeira AC, Mendez-Otero R, Dos Santos RR, Soares MB (2016) Zika virus infection induces mitosis abnormalities and apoptotic cell death of human neural progenitor cells. Sci Rep 6:39775. Scholar
  27. 27.
    Lubin JA, Zhang RR, Kuo JS (2018) Zika virus has oncolytic activity against glioblastoma stem cells. Neurosurgery 82(5):E113–E114. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Robert E. Means
    • 1
  • Sounak Ghosh Roy
    • 1
  • Samuel G. Katz
    • 1
    Email author
  1. 1.Department of PathologyYale School of MedicineNew HavenUSA

Personalised recommendations